News | May 26, 2025
Divi's Laboratories inks manufacturing and supply agreement with global pharma company
The company expects meaningful revenue contribution from this long-term agreement
The company expects meaningful revenue contribution from this long-term agreement
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore
Record international participation reflects renewed momentum in pharma manufacturing and global sourcing, as easing tariffs fuel growth
For the full year FY25, net profit soared 12x to Rs 345 crore
Allopurinol is used to prevent or lower high uric acid levels in the blood
Amlodipine and Atorvastatin tablets are indicated in patients for whom treatment with both amlodipine and atorvastatin
Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa's Recombinant Human Albumin in Europe
Isotretinoin capsules are indicated to treat severe, disfiguring nodular acne
The company was awarded the insulins supply contract for a three-year period in 2022 through April 2025
Subscribe To Our Newsletter & Stay Updated
